Selected article for: "advanced glycation end and glycation end"
Author: Chiappalupi, Sara; Salvadori, Laura; Donato, Rosario; Riuzzi, Francesca; Sorci, Guglielmo
Title: Hyperactivated RAGE in Comorbidities as a Risk Factor for Severe COVID-19—The Role of RAGE-RAS Crosstalk
  • Cord-id: yn2w9zok
  • Document date: 2021_6_12
    • ID: yn2w9zok
    Snippet: The receptor for advanced glycation-end products (RAGE) is a multiligand receptor with a role in inflammatory and pulmonary pathologies. Hyperactivation of RAGE by its ligands has been reported to sustain inflammation and oxidative stress in common comorbidities of severe COVID-19. RAGE is essential to the deleterious effects of the renin–angiotensin system (RAS), which participates in infection and multiorgan injury in COVID-19 patients. Thus, RAGE might be a major player in severe COVID-19,
    Document: The receptor for advanced glycation-end products (RAGE) is a multiligand receptor with a role in inflammatory and pulmonary pathologies. Hyperactivation of RAGE by its ligands has been reported to sustain inflammation and oxidative stress in common comorbidities of severe COVID-19. RAGE is essential to the deleterious effects of the renin–angiotensin system (RAS), which participates in infection and multiorgan injury in COVID-19 patients. Thus, RAGE might be a major player in severe COVID-19, and appears to be a useful therapeutic molecular target in infections by SARS-CoV-2. The role of RAGE gene polymorphisms in predisposing patients to severe COVID-19 is discussed.

    Search related documents:
    Co phrase search for related documents
    • ace inhibitor and acei ace inhibitor treatment: 1, 2
    • ace inhibitor and acei treatment: 1, 2, 3
    • ace inhibitor and acute coronary syndrome: 1
    • ace inhibitor and acute pneumonia: 1, 2, 3
    • ace inhibitor and acute pneumonia ards respiratory distress syndrome: 1
    • ace inhibitor and acute sars respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • ace inhibitor and additional age: 1
    • ace inhibitor and adipose tissue: 1
    • ace inhibitor and lung damage: 1
    • ace inhibitor and lung disease: 1
    • ace inhibitor and lung injury: 1, 2, 3, 4
    • ace inhibitor and lung tissue: 1, 2, 3, 4
    • ace inhibitor and macrophage release: 1